Abstract:Objective:To evaluate the results of neuroblastoma (NB) based upon risk-adapted therapy.Methods:From September 2002 to December 2018, clinical data were reviewed for 483 newly diagnosed NB patients aged ≤18 years based on risk-adapted therapy. They were stratified into low, intermediate and high-risk groups by age, stage, histological category and MYCN status. There were 290 males and 193 females with a median diagnostic age of 3.5 years (7 days to 18 years). The stages were 1 (n=19) , 2 (n=25) , 3 (n=95) , 4 (n=334) and 4S (n=10). Surgery alone or surgery plus low intensive chemotherapy for low-risk group (n=46, 9.5%) ; Surgery plus moderate intensive chemotherapy with or without radiotherapy for intermediate-risk group (n=102, 21.1%) ; For high-risk group (n=335, 69.4%) , before 2013, the treatment strategies included 8 cycles of alternating chemotherapy of cyclophosphamide (CTX) + vincristine (VCR) + pirarubicin (THP) and cisplatin (DDP) + etoposide (VP16) , surgery, with or without autologous hematopoietic stem cell transplantation (ASCT) , radiotherapy, with or without biotherapy and isotretinoin maintenance therapy for 1 year; after 2013, 8 cycles of alternating chemotherapy of CTX + VCR + THP and VP16 + ifosfamide + DDP protocol, surgery, radiotherapy, with or without biological therapy and oral maintenance chemotherapy drugs for 1 year. Recurrent patients received salvage therapy.Results:MYCN amplification was 22.4 % (72/322) in all groups and 33.8%(72/213) in high-risk group. ASCT was performed for only 15 cases. During a median follow-up period of 38(2.5-208) months, 3-year event-free survival (EFS) and overall survival (OS) were (86.5±5.1) % and 100% for low-risk group ; (79.1±4.3)% and (89.2±3.3) % for intermediate-risk group ; (30.6±2.7)% and (60.3±2.9)% for high-risk group respectively. Univariate survival analysis of 335 high-risk patients indicated that stage 4 and chemotherapy alone were poor prognostic factors for EFS/OS. Multivariate survival analysis showed that stage 4 and chemotherapy alone were independent adverse prognostic factors for EFS in high-risk NB patients while stage 4, chemotherapy alone and primary abdominal lesions were independent adverse prognostic factors for OS in high-risk NB patients. The 3-year EFS for MYCN positive high-risk patients was (27.4±6.3) % and for MYCN negative high-risk patients (36.7±4.4) % and the inter-group difference was statistically significant ( P=0.049). The 3-year EFS for MYCN positive high-risk patients with stage 4 was (18.7±6.7) % and for MYCN positive high-risk patients with stage 3/4S was (49.4±13.1) % and the inter-group difference was statistically significant ( P=0.009). In high-risk complete/partial remission patients without ASCT, 3-year EFS of oral isotretinoin maintenance therapy was (28.0±5.1)% while 3- year EFS of oral chemotherapy maintenance therapy was (42.1±5.1)% and the inter-group difference was statistically significant ( P=0.019). In high-risk patients, 3-year EFS for the therapeutic model of chemotherapy + surgery + radiotherapy was 37.1% , 19.0% for chemotherapy + surgery and 7.7% for chemotherapy alone. And the inter-group differences were statistically significant ( P<0.001). The 3-year EFS in high-risk group was (21.5±4.1 ) % before 2013 and (34.9±3.6) % after 2013. And the inter-group difference was statistically significant ( P=0.004) ; 3- year OS in high-risk group was (47.7±4.9)% before 2013 and (66.7±3.6) % after 2013. And the inter-group difference was statistically significant ( P<0.001). Conclusions:NB may be stratified into low, intermediate and high-risk groups based upon age, stage, histological category and MYCN status. For risk-adapted therapy, low and intermediate groups have better survival. High-risk patients have poor survival and new therapy should be explored. Salvage therapy for recurrent NB offers a survival benefit.

Evaluation of the Outcomes of Autologous Hematopoietic Stem Cells Transplantation on the Treatment of Children with Advanced Neuroblastoma

Clinical Report on the Treatment of Children with Advanced Neuroblastoma with Autologous Haematopoietic Stem Cell Transplantation.

[Effectiveness of autologous hematopoietic stem cell transplantation in the treatment of high-risk neuroblastoma in children: a single-center clinical study]

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

Analysis of the Efficacy of Autologous Peripheral Blood Stem Cell Transplantation in High-Risk Neuroblastoma

[Therapeutic Experience of Childhood Stage III Neuroblastoma].

[Comprehensive Protocol for Diagnosis and Treatment of Childhood Neuroblastoma--results of 45 Cases].

Prognostic Influence of Minimal Residual Disease Detected by Flow Cytometry and Peripheral Blood Stem Cell Transplantation by CD34+ Selection in Childhood Advanced Neuroblastoma.

Results of the Neuroblastoma-2015 Protocol for Treating Neuroblastoma in China: Experience from Multiple Centers

Outcome analysis of neuroblastoma based upon risk-adapted therapy: a report of 483 cases

The Feasibility Study for VGPR As the End of Treatment in Children with Ⅰ-Ⅲ Neuroblastoma

Treatment of stage IV neuroblastoma with allogeneic hematopoietic stem cell transplantation in children

[Long-Term Follow-Ups of Comprehensive Therapies for Stage 4 Neuroblastoma].

[Treatment of Advanced Malignant Solid Tumors in Children with Autologous Hematopoietic Stem Cell Transplantation].

[Evaluation of Efficacy of Treatment for 30 Children with Neuroblastoma].

The role of surgical treatment in children with stage Ⅳ neuroblastoma

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

Analysis of curative effect of the NB09 protocol based on 95 children with stage 4 neuroblastomas

Pediatric high risk neuroblastoma with autologous stem cell transplant - 20 years of experience

Long term follow-up of children with neuroblastoma without chemotherapy and radiotherapy

Clinical Outcomes of Children with Neuroblastoma under Multidisciplinary Treatment